← Back to Screener
Apellis Pharmaceuticals, Inc. Common Stock (APLS)
Price$40.94
Favorite Metrics
Price vs S&P 500 (26W)54.07%
Price vs S&P 500 (4W)128.16%
Market Capitalization$5.23B
P/E Ratio (Annual)233.76x
All Metrics
P/CF (Annual)115.46x
Book Value / Share (Quarterly)$2.92
P/TBV (Annual)33.76x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)137.00%
Cash Flow / Share (Quarterly)$0.36
Price vs S&P 500 (YTD)58.68%
Gross Margin (TTM)89.81%
Net Profit Margin (TTM)2.23%
EPS (TTM)$0.12
10-Day Avg Trading Volume5.31M
EPS Excl Extra (TTM)$0.12
Revenue Growth (5Y)31.99%
EPS (Annual)$0.18
ROI (Annual)2.71%
Gross Margin (Annual)89.81%
Net Profit Margin (5Y Avg)-428.42%
Cash / Share (Quarterly)$3.68
P/E Basic Excl Extra (TTM)233.76x
Revenue Growth QoQ (YoY)-5.94%
P/E Normalized (Annual)233.76x
ROA (Last FY)2.08%
Revenue Growth TTM (YoY)28.46%
EBITD / Share (TTM)$0.45
ROE (5Y Avg)-222.36%
Operating Margin (TTM)5.52%
Cash Flow / Share (Annual)$0.36
P/B Ratio14.14x
P/B Ratio (Quarterly)8.59x
Net Income / Employee (Annual)$0
EV / Revenue (TTM)5.20x
Net Interest Coverage (TTM)1.77x
ROA (TTM)2.38%
EV / EBITDA (TTM)91.86x
EPS Incl Extra (Annual)$0.18
Current Ratio (Annual)3.14x
Quick Ratio (Quarterly)2.59x
3-Month Avg Trading Volume4.36M
52-Week Price Return125.22%
EV / Free Cash Flow (Annual)116.02x
P/E Incl Extra (TTM)233.76x
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$1.96
P/S Ratio (Annual)5.21x
Asset Turnover (Annual)0.93x
52-Week High$40.95
Operating Margin (5Y Avg)-386.90%
EPS Excl Extra (Annual)$0.18
CapEx CAGR (5Y)-43.47%
Tangible BV CAGR (5Y)2.66%
26-Week Price Return62.82%
Quick Ratio (Annual)2.59x
13-Week Price Return101.18%
Total Debt / Equity (Annual)1.23x
Current Ratio (Quarterly)3.14x
Enterprise Value$5,222.449
Revenue / Share Growth (5Y)19.02%
Asset Turnover (TTM)1.07x
Book Value / Share Growth (5Y)1.69%
Revenue / Employee (Annual)$1
Inventory Turnover (Annual)0.91x
Pretax Margin (Annual)2.40%
Cash / Share (Annual)$3.68
3-Month Return Std Dev269.54%
Gross Margin (5Y Avg)88.95%
Net Income / Employee (TTM)$0
ROE (Last FY)6.05%
Net Interest Coverage (Annual)1.77x
EPS Basic Excl Extra (Annual)$0.18
P/FCF (TTM)39.63x
Receivables Turnover (TTM)3.18x
EV / Free Cash Flow (TTM)116.02x
Total Debt / Equity (Quarterly)1.23x
EPS Incl Extra (TTM)$0.12
Receivables Turnover (Annual)3.18x
ROI (TTM)3.08%
P/S Ratio (TTM)5.21x
Pretax Margin (5Y Avg)-427.94%
Revenue / Share (Annual)$7.96
Tangible BV / Share (Annual)$1.53
Price vs S&P 500 (52W)90.13%
P/E Ratio (TTM)233.76x
Year-to-Date Return62.82%
5-Day Price Return0.15%
EPS Normalized (Annual)$0.18
ROA (5Y Avg)-51.55%
Net Profit Margin (Annual)2.23%
Month-to-Date Return1.67%
Cash Flow / Share (TTM)$-5.21
EBITD / Share (Annual)$0.45
Operating Margin (Annual)5.52%
LT Debt / Equity (Annual)0.98x
P/CF (TTM)115.46x
ROI (5Y Avg)-64.42%
P/E Excl Extra (TTM)233.76x
LT Debt / Equity (Quarterly)0.98x
EPS Basic Excl Extra (TTM)$0.12
P/TBV (Quarterly)24.69x
P/B Ratio (Annual)8.59x
Inventory Turnover (TTM)0.91x
Pretax Margin (TTM)2.40%
Book Value / Share (Annual)$2.92
Price vs S&P 500 (13W)98.32%
Beta-0.24x
P/FCF (Annual)116.26x
Revenue / Share (TTM)$7.92
ROE (TTM)8.20%
52-Week Low$16.10
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
3.89
3.96
3.93
3.56
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
APLSApellis Pharmaceuticals, Inc. Common Stock | 5.21x | 28.46% | 89.81% | — | $40.94 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Apellis Pharmaceuticals commercializes complement system inhibitors for diseases with significant unmet treatment needs. The company markets two C3-targeted therapies, SYFOVRE and EMPAVELI (both pegcetacoplan-based), which inhibit a central immune pathway and represent meaningful commercial opportunities in complement-driven immune diseases.